Are Amgen and Gilead Sciences Better Buys After Second-Quarter Earnings?
The period from May through late July tends to be unexciting for biotech stocks, in part because for various logistical reasons, first-quarter earnings are usually ho-hum across the industry. Second-quarter earnings, though, are often much stronger, which provides a spark for share prices.
With that in mind, let's consider Amgen (NASDAQ: AMGN) and Gilead Sciences (NASDAQ: GILD), both of which released their Q2 results after the closing bell Tuesday. Are either of these biotech heavyweights more compelling buys in the wake of their earnings reports?
Image Source: Getty Images.
Quelle Fool.com
